| Literature DB >> 26771605 |
Roberta Lotti1, Elisabetta Palazzo2, Tiziana Petrachi3, Katiuscia Dallaglio4, Annalisa Saltari5, Francesca Truzzi6, Marika Quadri7, Mario Puviani8, Antonino Maiorana9, Alessandra Marconi10, Carlo Pincelli11.
Abstract
Squamous Cell Carcinoma-derived Stem-like Cells (SCC-SC) originate from alterations in keratinocyte stem cells (KSC) gene expression and sustain tumor development, invasion and recurrence. Since survivin, a KSC marker, is highly expressed in SCC-SC, we evaluate its role in SCC-SC cell growth and SCC models. Survivin silencing by siRNA decreases clonal growth of SCC keratinocytes and viability of total, rapidly adhering (RAD) and non-RAD (NRAD) cells from primary SCC. Similarly, survivin silencing reduces the expression of stem cell markers (OCT4, NOTCH1, CD133, β₁-integrin), while it increases the level of differentiation markers (K10, involucrin). Moreover, survivin silencing improves the malignant phenotype of SCC 3D-reconstruct, as demonstrated by reduced epidermal thickness, lower Ki-67 positive cell number, and decreased expression of MMP9 and psoriasin. Furthermore, survivin depletion by siRNA in Ras(G12V)-IκBα-derived tumors leads to smaller tumor formation characterized by lower mitotic index and reduced expression of the tumor-associated marker HIF1α, VEGF and CD51. Therefore, our results indicate survivin as a key gene in regulating SCC cancer stem cell formation and cSCC development.Entities:
Keywords: differentiation; rapidly adhering cells; skin; squamous cell carcinoma; stem cells; survivin; tumor formation; tumorigenesis; β1-integrin
Mesh:
Substances:
Year: 2016 PMID: 26771605 PMCID: PMC4730332 DOI: 10.3390/ijms17010089
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Survivin inhibition decreases cSCC cell proliferation, clonogenic ability and stemness features. (A) cSCC cell ability to proliferate in vitro after transfection with scramble or survivin siRNA was evaluated by MTT (3-4,5-dimethylyhyazol-2-y1)-2,5-diphenyltetrazolium bromide) assay; (B) Clonal growth assessment of cSCC cells after transfection with scramble or survivin siRNA by CFE. CFE was performed in triplicate in three independent experiments and quantified; ** p < 0.01; (C) Percentage of colonies with respect to size obtained from CFE assay; (D) Expression of stem cell and differentiation markers in scramble or survivin siRNA transfected cSCC cells. Cells were analysed 24 h after transfection, and levels of markers were determined by Western blot analysis. β-actin was used as loading control; (E) Representative pictures of RAD, NRAD and cSCC bulk cells after transfection with scramble or survivin siRNA, 24 h post-treatment. Scale bar = 200 µm; (F) Relative cell density evaluated by ImageJ software analysis (* 0.01 < p < 0.05; ** p < 0.01).
Figure 2Survivin depleted RAD and NRAD-derived skin reconstructs. (A) Left panel: Hematoxilin and Eosin staining of survivin siRNA-treated RAD and NRAD SCC13 derived skin reconstructs. Right panel: Bar graph representing epidermal thickness (micron) of survivin siRNA-treated RAD and NRAD SCC13 derived skin reconstructs. Scale bar = 120 µm; (B) Bar graph representing the number of Ki-67 positive cells; (C) MMP9 and psoriasin expression evaluated by immunohistochemistry in siRNA-treated RAD and NRAD SCC13 derived skin reconstructs, with the table indicating the relative scores: - not expressed; + poorly expressed; ++ moderately expressed; +++ well expressed. The images are representative of three independent experiments. (* 0.01 < p < 0.05; ** p < 0.01). Scale bar = 120 µm.
Figure 3Survivin silencing decreases cell viability in RasG12V-IκBαM-transduced keratinocytes. (A) Expression of survivin in scramble or survivin siRNA transfected NoLacZ or RasG12V-IκBαM-transduced keratinocytes. Cells were analysed 48 h after transfection, and levels of markers were determined by Western blot analysis. β-actin was used as loading control; (B) Survivin siRNA transfected NoLacZ or RasG12V-IκBαM-transduced keratinocytes ability to proliferate in vitro evaluated by MTT assay 72 h after transfection; (C) Survivin, pan-keratin, H-Ras and IκBα staining in survivin siRNA transfected NoLacZ or RasG12V-IκBαM tumors evaluated by immunofluorescence. (** = p < 0.01). Scale bar = 200 µm.
Evaluation of in vivo tumor formation after sub-cutaneous injection of human keratinocytes infected with retroviral vector expressing Ha-RasG12V and IκBαM in presence or in absence of endogenous survivin.
| Condition | Tumour at 4 Weeks | Tumour at 6 Weeks | Tumour Size (cm3 ± SD) |
|---|---|---|---|
| NoLacZ Scramble | − (3/3) | + (3/3) | 0.49 ± 0.17 |
| NoLacZ Survivin siRNA | − (3/3) | + (3/3) | 0.39 ± 0.14 |
| RasG12V-IκBαM Scramble | + (3/3) | + (3/3) | 0.89 ± 0.33 |
| RasG12V-IκBαM Survivin siRNA | − (3/3) | + (3/3) | 1.01 ± 0.38 |
Figure 4Survivin silencing decreases the malignant phenotype of RasG12V-ΙκΒαΜ-derived tumors. (A) Hematoxilin and Eosin staining of survivin siRNA-treated RasG12V-ΙκΒαΜ-derived tumors; (B) Mitotic Index representing the number of cells undergoing mitosis over total cells. Scale bars = 200 µm; (C) HIF1α staining in survivin siRNA transfected NoLacZ or RasG12V-ΙκΒαΜ tumors evaluated by immunofluorescence; (D) VEGF staining in survivin siRNA transfected NoLacZ or RasG12V-ΙκΒαΜ tumors evaluated by immunofluorescence; (E) CD51 staining in survivin siRNA transfected NoLacZ or RasG12V-ΙκΒαΜ tumors evaluated by immunofluoresce; (F) HIF1α (upper panel) and CD51 (lower panel) positive cell count assessed by ImageJ software (* 0.01 < p < 0.05; ** p < 0.01). Scale bars = 200 µm.